Jia Zhong

Education
Sc.D., environmental health, Harvard T.H. Chan School of Public Health; M.S., biochemistry and molecular biology, Chinese Academy of Sciences; B.S., applied molecular biology, Zhejiang University, China
Summary of Experience
Dr. Zhong is an epidemiologist who specializes in clinical health economics and outcomes research (HEOR), clinical trials, and large-scale epidemiological studies. She has more than 15 years’ research experience in disease areas such as hematology, pulmonary diseases, diabetes, cardiovascular diseases, oncology, rare diseases, and immunology. Dr. Zhong’s expertise includes comparative efficacy and safety, individualized medicine, predictive modeling, and longitudinal analysis. Her recent work includes leading large-scale prospective cohort studies, evaluating the comparative efficacy of immuno-oncology treatments for regulatory submissions, quantifying direct and indirect resource utilization and costs, and evaluating real-world effectiveness using patient reported outcomes (PROs). Her research has been published in Nature Immunology, Immunity, Proceedings of the National Academy of Sciences, Circulation, Circulation Research, Hypertension, and the International Journal of Epidemiology, among other publications. Prior to joining Analysis Group, Dr. Zhong was a research scientist at the Columbia University Mailman School of Public Health, where she developed data-based therapeutic target identification frameworks.
-
Treatment Patterns and FLT3 Mutation Testing Among Patients with Acute Myeloid Leukemia in China: A Retrospective Observational Study
Therapeutics and Clinical Risk Management, 2024
2024Gong B, Cheng LJ, Young CH, Krishnan P, Wang Y, Wei H, Zhou C, Wei S, Li Y, Fang Q, Zhong J, Wu EQ, Mi Y, Wang J
HEOR, Epidemiology & Market Access -
Real-world Data for Healthcare Research in China: Call for Actions
Value in Health Regional Issues, Volume 27, 2022
2022Xie J, Wu EQ, Wang S, Cheng T, Zhou Z, Zhong J, Liu L
HEOR, Epidemiology & Market Access -
Advancing the development of real-world data for healthcare research in China: challenges and opportunities
BMJ Open, 2022
2022Zhong J, Zhang J, Fang H, Liu L, Xie J, Wu E
HEOR, Epidemiology & Market Access -
Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A
Journal of Managed Care & Specialty Pharmacy, 2020
2020Zhou ZY, Raimundo K, Patel A, Han S, Ji Y, Fang H, Zhong J, Betts K, Mahajerin A
HEOR, Epidemiology & Market Access -
Prevalence and economic burden of hyperkalemia in the United States Medicare population
Current Medical Research and Opinion
2020Mu F, Betts KA, Woolley JM, Dua A, Wang Y, Zhong J, Wu EQ
HEOR, Epidemiology & Market Access -
An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies
Haemophilia, 27 November 2020
2020Song X, Zhong J, Xue F, Chen L, Li H, Yuan D, Xie J, Shi J, Zhang L, Wu E, Yang R
HEOR, Epidemiology & Market Access -
Real‐world analysis of haemophilia patients in China: A single centre’s experience
Haemophilia, 20 May 2020
2020Song X, Liu W, Xue F, Zhong J, Yang Y, Liu Y, Xie, J, Wu E, Zhang L, Shi J, Yang R
HEOR, Epidemiology & Market Access -
Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real-World Population
JBMR Plus, 2020
2020Kilpatrick RD, Chiuve SE, Leslie WD, Wegrzyn LR, Gao W, Yang H, Soliman AM, Snabes MC, Koenigsberg S, Zhong J, Xiang C, Watts NB
HEOR, Epidemiology & Market Access -
The cost-effectiveness of low-dose budesonide as a Step 2 treatment for pediatric asthma in China
Journal of Comparative Effectiveness Research, 2020
2020Wang X, Fang H, Shen K, Liu T, Xie J, Liu Y, Zhong J, Wu E, Zhou W, Wu B
HEOR, Epidemiology & Market Access -
Cost-effectiveness analysis of double low-dose budesonide and low-dose budesonide plus montelukast among pediatric patients with persistent asthma receiving Step 3 treatment in China
Journal of Medical Economics, 2020
2020Wang X, Fang H, Shen K, Liu T, Xie J, Liu Y, Wu P, Chen Y, Zhong J, Wu E, Zhou W, Wu B
HEOR, Epidemiology & Market Access
-
May 15, 2022
Analysis Group Health Care Consultants to Present at ISPOR 2022
Event: ISPOR 2022
Host: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) -
June 19, 2022
Manager Jia Zhong to Discuss Real-World Evidence for Rare Conditions at ICSA 2022
Event: ICSA 2022 Applied Statistics Symposium
Host: International Chinese Statistical Association (ICSA) -
November 6, 2022
Analysis Group HEOR Consultants Present at ISPOR Europe 2022
Event: ISPOR Europe 2022
Host: ISPOR – The International Society for Pharmacoeconomics and Outcomes Research -
November 12, 2023
Analysis Group HEOR Consultants to Present at ISPOR Europe 2023
Event: ISPOR Europe 2023
Host: ISPOR – The International Society for Pharmacoeconomics and Outcomes Research
-
December 19, 2024
-
December 6, 2023
-
June 27, 2023
-
November 1, 2022
-
May 12, 2022
-
March 1, 2022
-
February 11, 2022
